Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Inclusion Criteria: Patients ≥18 years old; ECOG score 0~1, organ function is good; Histologically confirmedfirst-line treatment for locally advanced or relapsed metastatic squamous cell carcinoma ofthe skin. There were measurable tumor lesions evaluated by MRI or CT during the 21 days prior toenrollment; If you have received antitumor therapy, the following conditions should be met:

1. The interval between systemic radiotherapy and the first dose in this study was ≥3weeks, and the interval between local radiotherapy was ≥2 weeks;
2. The interval between previous chemotherapy, targeted therapy, biotherapy, endocrinetherapy and other antitumor therapies and the first administration in this study was ≥4 weeks; Normal function of major organs (within 14 days prior to treatment); Forfemale patients who are not menopausal or have not been surgically sterilized: consentto abstinence from sex or use of effective contraceptive methods during treatment andfor at least 7 months after the last dose in the study treatment; The patientsvoluntarily participated in this study and signed the informed consent. Who can be included as judged by the researcher.

Exclusion Criteria: Previously received anti-PD-1, anti-PD-L1, anti-PD-L2 drug therapy; Also receivingantitumor therapy in other clinical trials; Had major surgical operations within 4 weeksprior to enrollment, or had not fully recovered from such operations; Serious heart diseaseor discomfort or concomitant disease that, according to the judgment of the investigator,seriously endangers the safety of the patient or affects the completion of the study;Allergic reactions: Patients who are allergic to the investigational drug or to anyinvestigational drug component in the chemotherapy regimen are not recommended forinclusion. Pregnant and lactating women, fertile women who tested positive for baseline pregnancytests, or patients of childbearing age who did not want to take effective contraceptivemeasures during the entire trial period and within 6 months after the last study; Thoseconsidered unsuitable for inclusion by researchers.